Tandem Diabetes Care Inc (TNDM) — Cash Flow Reinvestment Rate

Latest as of March 2026: 17.68x

Tandem Diabetes Care Inc (TNDM) has a Cash Flow Reinvestment Rate of 17.68x as of March 2026, reinvesting $195.45 Million (capex $6.27 Million plus investments $-189.18 Million) from operating cash flow of $11.05 Million. Check cash flow quality index of Tandem Diabetes Care Inc to evaluate the quality of earnings relative to operating cash generation.

Reinvestment Rate

17.68x
(Capex + Investments) / Operating CF

Total Reinvested

$195.45 Million
Capex + Investments

Operating Cash Flow

$11.05 Million
USD

Capital Expenditures

$6.27 Million
USD

Tandem Diabetes Care Inc Cash Flow Reinvestment Rate (2019–2024)

Historical reinvestment intensity for Tandem Diabetes Care Inc across 5 annual periods. Explore Tandem Diabetes Care Inc long-term investment allocation to see how much of total assets are deployed in long-term investments.

Annual Cash Flow Reinvestment Rate for Tandem Diabetes Care Inc (2019–2024)

Year-by-year capital reinvestment analysis for Tandem Diabetes Care Inc. For live market cap and broader valuation context, see TNDM company net worth.

Year Reinvestment Rate Total Reinvested (USD) Operating CF Capex YoY Change
2024 1.76x $42.71 Million $24.23 Million $19.23 Million ▲ +32.3%
2022 1.33x $67.27 Million $50.46 Million $34.10 Million ▼ -20.6%
2021 1.68x $186.88 Million $111.36 Million $23.51 Million ▼ -86.0%
2020 12.00x $296.06 Million $24.67 Million $32.29 Million ▲ +783.0%
2019 1.36x $56.95 Million $41.91 Million $19.54 Million
Cash Flow Reinvestment Rate = (ABS(Capex) + ABS(Investments)) / Operating Cash Flow